RE:RE:RE:RE:Conditions are right for biopharma M&A to break outBiotech M&A deals have tallied $64 billion so far this year. In the last few weeks alone, Pfizer said it will pay $43 billion for Seagen; Merck agreed to acquire Prometheus Biosciences for $10.8 billion; and GSK said it will buy Bellus Health for $2 billion. According to Tim Opler at Torreya (who referenced his firm’s research), “It’s a blistering pace on track for $300 billion by year’s end, which could approach the all-time deal record of $328 billion in 2019.”